Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation

ESMO Congress 2022

9 - 13 Sep 2022

Published: 12 Sep 2022

Views: 117

Rating:

Save

Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

Dr Melissa Johnson presents the primary analysis of the phase 3 CodeBreaK 200 trial comparing sotorasib versus docetaxel in previously treated KRAS G12C-mutated NSCLC.

In this first, randomised phase 3 trial for a KRAS G12C inhibitor, oral sotorasib demonstrated superior PFS and ORR compared to intravenous docetaxel and had a more favourable safety profile.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

OncoAlert Round Up for August 4th - 10th, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 4th - 10th, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

The use of IORT at Universitätsmedizin Mannheim hospital

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany

The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

Advancing breast cancer diagnosis in the developing world

Dr Hans Junkermann, Prof Dr.Erkin Arıbal and Dr Richard Rainsbury

Advancing breast cancer diagnosis in the developing world ( Dr Hans Junkermann, Prof Dr.Erkin Arıbal and Dr Richard Rainsbury )

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...

Dr Ian Krop - Yale Cancer Center, Connecticut, USA

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk...

Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML ( Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA )

More from ecancer